Compare VALN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | CMPS |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | France | United Kingdom |
| Employees | N/A | 166 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 875.7M | 778.7M |
| IPO Year | 2021 | 2020 |
| Metric | VALN | CMPS |
|---|---|---|
| Price | $11.30 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $15.75 | ★ $27.14 |
| AVG Volume (30 Days) | 17.1K | ★ 4.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.58 | N/A |
| Revenue Next Year | $4.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.43 | $2.25 |
| 52 Week High | $12.25 | $8.90 |
| Indicator | VALN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 54.27 |
| Support Level | $8.37 | $5.95 |
| Resistance Level | $12.22 | $8.20 |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 59.63 | 43.69 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.